-
1دورية أكاديمية
المؤلفون: Mabel Sarpong-Duah, Michael Frimpong, Marcus Beissner, Malkin Saar, Ken Laing, Francisca Sarpong, Aloysius Dzigbordi Loglo, Kabiru Mohammed Abass, Margaret Frempong, Fred Stephen Sarfo, Gisela Bretzel, Mark Wansbrough-Jones, Richard Odame Phillips
المصدر: PLoS Neglected Tropical Diseases, Vol 11, Iss 7, p e0005695 (2017)
مصطلحات موضوعية: Arctic medicine. Tropical medicine, RC955-962, Public aspects of medicine, RA1-1270
وصف الملف: electronic resource
العلاقة: http://europepmc.org/articles/PMC5510892?pdf=renderTest; https://doaj.org/toc/1935-2727Test; https://doaj.org/toc/1935-2735Test
-
2
المؤلفون: Alan Knell, Thomas Berko, Linda Lehman, Tuah Wilson, Sarah Eyangoh, Kingsley Asiedu, Ernest Opoku, Kristien Velding, Edwin Ampadu, Jérôme Robert, Estelle Marion, Bright Osei-Wusu, Annick Chauty, Edward Sarpong, William Faber, Anastasia Nsiah, Ambroise Adeye, Yaw Ampem Amoako, Marie Françoise Ardent, William Thompson, George Amofa, Richard Phillips, Line Ganlonon, John M Macdonald, Elliot Koranteng Tannor, Till F. Omansen, Raymond Omollo, Terry Treadwell, Justice Abotsi, Albert Paintsil, Nanaa Francisca Sarpong, Samuel Osei Mireku, Maxime Kiki, Raoul Saizonou, David Ofori-Adjei, Bernadette Agbavor, Godfred Sarpong, Espoir Sodjinou, Michael Ochieng Otieno, Fred Stephen Sarfo, Paul Saunderson, Aloysius Dzibordzi Loglo, Martial Kindjinou, Justice K. Boakye-Appiah, Beatrice Konadu, Arnaud Yamadjako, Didier Agossadou, Mark Forson, Tjip S. van der Werf, Sally-Ann Ohene, Elizabeth Ofori, Mathias Ndogyele, Ymkje Stienstra, Thaddaeus Egondi, Richard Asamoah-Frimpong, Joseph Ken Adu Poku, Mabel Sarpong-Duah, Joyce Mensah-Bonsu, Felicity Aboagye, Thierry Gateau, Michael Frimpong, Joseph Ofori Nyarko, Mark Wansbrough-Jones, Kabiru Mohamed Abass, Clémence Guegnard, Alexandre Tiendrebeogo, Akpolan, Jacques H. Grosset, Sandor-Adrian Klis, Naomi Adanmado Gersande
المساهمون: Bernardo, Elizabeth, Identification and development of vaccine candidates for Buruli Ulcer Disease - BURULIVAC - - EC:FP7:HEALTH2010-03-01 - 2013-05-31 - 241500 - VALID, Kwame Nkrumah University of Science and Technology [GHANA] (KNUST), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Agogo Presbyterian Hospital [GHANA], NkawieToaso Government Hospital [GHANA], Centre de diagnostic et de traitement de la lèpre et de l’Ulcère de Buruli Madeleine et Raoul Follereau [Pobè, Bénin], Drugs for Neglected Diseases initiative [Nairobi, Kenya] (ARO), Africa Regional Office [Nairobi, Kenya], National Buruli ulcer Control Programme [Accra, Ghana] (GHS), Ghana Health Service [Accra, Ghana], Programme National de Lutte contre la lèpre et l’Ulcère de Buruli [Cotonou, Benin], ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), St George's, University of London, Johns Hopkins University (JHU), University of Miami Leonard M. Miller School of Medicine (UMMSM), Institute for Advanced Wound Care [Montgomery, AL, USA], American Leprosy Missions [Greenville, SC, USA], Korle-BU Teaching Hospital [Accra, Ghana], WHO, Country Office for Benin [Cotonou, Benin], WHO, Regional Office for Africa [Brazzaville, Republic of the Congo], WHO, Country Office for Ghana [Accra, Ghana], University Medical Center Groningen [Groningen] (UMCG), Department of Neglected Tropical Diseases, WHO [Geneva, Switzerland], WHO sponsored the study with additional support in cash or kindprovided by MAP International, American Leprosy Missions, Fondation Raoul Follereau France, Buruli ulcer Groningen Foundation, SanofiPasteur France, and BuruliVac (EU FP7-241500)., European Project: 241500,EC:FP7:HEALTH,FP7-HEALTH-2009-single-stage,BURULIVAC(2010), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Microbes in Health and Disease (MHD), Kwame Nkrumah University of Science and Technology (KNUST)
المصدر: The Lancet
The Lancet, 2020, 395 (10232), pp.1259-1267. ⟨10.1016/S0140-6736(20)30047-7⟩
The Lancet, Elsevier, 2020, 395 (10232), pp.1259-1267. ⟨10.1016/S0140-6736(20)30047-7⟩
The Lancet, 395(10232), 1259-1267. ELSEVIER SCIENCE INCمصطلحات موضوعية: Male, Buruli ulcer, Administration, Oral, 030204 cardiovascular system & hematology, Ghana, DISEASE, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Clarithromycin, INFECTION, Clinical endpoint, Benin, Medicine, EPIDEMIOLOGY, 030212 general & internal medicine, Child, Buruli Ulcer, education.field_of_study, biology, General Medicine, Anti-Bacterial Agents, 3. Good health, Tolerability, Mycobacterium ulcerans, Streptomycin, MYCOBACTERIUM-ULCERANS, Drug Therapy, Combination, Female, Rifampin, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Young Adult, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Humans, education, COMBINATION, Wound Healing, business.industry, medicine.disease, biology.organism_classification, EFFICACY, Regimen, Delayed-Action Preparations, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c62a9e4b664859cb8d5027e0d0cbcadTest
https://doi.org/10.1016/S0140-6736Test(20)30047-7 -
3
المؤلفون: Sophie Duraffour, Florian Kurth, Stephan Günther, Osahogie I. Edeawe, Michael Ramharter, Mirjam Groger, Sylvanus Okogbenin, Till Koch, Cyril O Erameh, Ephraim Ogbaini-Emovon, Sebastian G. Wicha, Francisca Sarpong, Gloria Eifediyi, Christine Wagner, Till Frederik Omansen, Lisa Oestereich, Meike Pahlmann, Peter E Akhideno
المصدر: BMJ Open
مصطلحات موضوعية: Adult, medicine.medical_specialty, Nigeria, law.invention, chemistry.chemical_compound, Lassa Fever, Pharmacokinetics, law, Internal medicine, Ribavirin, Medicine, Humans, Prospective Studies, Lassa fever, Volume of distribution, Clinical pharmacology, business.industry, General Medicine, medicine.disease, virology, Regimen, Observational Studies as Topic, Infectious Diseases, chemistry, Research Design, Good clinical practice, Observational study, clinical pharmacology, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788bb4cd60a396ee96f4648c1225f9e1Test
http://europepmc.org/articles/PMC7200043Test